GSK's targeted cancer therapy shows positive results in late-stage study

GSK reported positive late-stage trial results for an experimental therapy in advanced or relapsed small-cell lung cancer. The update is supportive for the drug’s development prospects, though no efficacy/safety magnitudes were provided in the excerpt.

Analysis

GSK reported positive late-stage trial results for an experimental therapy in advanced or relapsed small-cell lung cancer. The update is supportive for the drug’s development prospects, though no efficacy/safety magnitudes were provided in the excerpt.